Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Jonathan W. Goldman, Peipei Shi, Martin Reck, Luis Paz-Ares, Andrew Koustenis, Karla C. Hurt

Open source

DOI
10.1016/j.cllc.2015.08.003
Published
2016-01
Container
Clinical Lung Cancer
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2015.08.003,
  title = {Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy},
  author = {Jonathan W. Goldman and Peipei Shi and Martin Reck and Luis Paz-Ares and Andrew Koustenis and Karla C. Hurt},
  year = {2016},
  journal = {Clinical Lung Cancer},
  doi = {10.1016/j.cllc.2015.08.003},
  url = {https://doi.org/10.1016/j.cllc.2015.08.003}
}

RIS

TY  - JOUR
TI  - Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy
AU  - Jonathan W. Goldman
AU  - Peipei Shi
AU  - Martin Reck
AU  - Luis Paz-Ares
AU  - Andrew Koustenis
AU  - Karla C. Hurt
PY  - 2016
JO  - Clinical Lung Cancer
DO  - 10.1016/j.cllc.2015.08.003
UR  - https://doi.org/10.1016/j.cllc.2015.08.003
ER  - 

APA

Goldman, J. W., Shi, P., Reck, M., Paz-Ares, L., Koustenis, A., & Hurt, K. C. (2016). Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2015.08.003

Source records